Preferred Label : pNGVL4a-Sig/E7(detox)/HSP70 DNA and HPV16 L2/E6/E7 Fusion Protein TA-CIN Vaccine PVX-2;
NCIt definition : A cancer vaccine consisting of a combination of two vaccines, a prime pNGVL4a-Sig/E7(detox)/HSP70
DNA vaccine and a boost HPV16 L2/E6/E7 fusion protein TA-CIN vaccine, with potential
immunostimulating and antineoplastic activities. pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
is an antigen-specific DNA cancer vaccine consisting of the coding sequences of a
signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16)
antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this prime
vaccine may generate potent cytotoxic CD8( ) T-cell responses against E7-expressing
tumor cells, resulting in tumor cell death. HPV16 L2/E6/E7 fusion protein TA-CIN vaccine
is a recombinant human papillomavirus (HPV), genetically engineered fusion protein
vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in
a single tandem fusion protein (TA-CIN; HPV16 L2\\E6\\E7). Upon administration, this
boost vaccine may stimulate the immune system to generate HPV16 E6\\E7-specific CD4
and CD8 T-cell responses as well as the induction of L2-specific antibodies. In addition,
this vaccine may prevent infection and the development of other HPV16-associated diseases.
L2, a minor viral capsid protein, is able to induce a strong antibody response against
certain HPV types.;
Molecule name : PVX 2; PVX-2;
NCI Metathesaurus CUI : CL1406087;
Origin ID : C172205;
UMLS CUI : C5417909;
Semantic type(s)
- concept_is_in_subset
